Pseudomyxoma Peritonei Clinical Trial
— TRANSCAPEOfficial title:
Prospective Case Series of Intestinal and Multivisceral Transplantation for Unresectable Mucinous Carcinoma Peritonei (TRANSCAPE)
The goal of this prospective phase 2 study is to assess the efficacy and safety of intestinal or multivisceral transplantation for participants with PMP not amenable to other curative-intent treatments. Participants will undergo intestinal/multivisceral transplantation. Participants will be followed for 12 months to assess efficacy and safety.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | December 31, 2025 |
Est. primary completion date | December 31, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Subjects must have histologically confirmed pseudomyxoma peritonei (PMP) - Both low-grade mucinous carcinoma peritonei (LMCP) or high-grade mucinous carcinoma (HMCP), with or without signet ring cells as well as primary or recurrent disease, will be eligible. - PMP disease does not have any extra-abdominal metastases, with the exception of pulmonary involvement (nodal, parenchymal, and pleural). - PMP disease is extensive and not amenable to operative management, with or without liver, pancreas, stomach, or abdominal wall involvement. - Definition of Non-Resectable Disease- - Non-resectable PMP disease will be defined as the presence of at least one of the following conditions: - 1) Extensive small bowel serosa involvement, where it is not possible to preserve at least 1.5-2 m of small bowel - 2) Extensive infiltration of the pancreatic surface - 3) Mesenteric involvement causing retraction - 4) Need for complete gastric resection - 5) Urete1ic obstruction - 6) Liver disease with no chance to achieve R0 resection with liver remnant volume > 30% - 7) Recurrent disease not amenable to further resection - Subjects do not have any other available curative treatment options. - Subjects can have previous abdominal operations, including CRS+HIPEC. - Age = 18 and = 75. - Pediatric participants were excluded as PMP is a disease that affects adults. Participants > 75 years of age are excluded as they are beyond the commonly accepted transplantability criteria. - Performance status ECOG = 1. - Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: - Subjects with peritoneal carcinomatous originating from an etiology other than PMP. - Subjects receiving any other investigational agents. - Subjects with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would either put participation at risk because of participation in the study, may influence the result of the study, or limit compliance with study requirements. - Pregnant women are excluded from this study because an intestinal transplant is a procedure that is not compatible with a viable pregnancy. - Subjects who are HIV-positive may be included in the study. HIV testing is required for the study as adequate HIV treatment is required prior to intestinal transplant due to the increased risk of infection following transplantation and treatment with immunosuppressive agents. |
Country | Name | City | State |
---|---|---|---|
United States | Cleveland Clinic Digestive Disease & Surgery Institute (DDSI), Case Comprehensive Cancer Center | Cleveland | Ohio |
Lead Sponsor | Collaborator |
---|---|
Case Comprehensive Cancer Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Overall Rate of Survival | To determine overall 12-month survival after intestinal or multivisceral transplantation in participants with unresectable PMP. | 12 months post operative | |
Secondary | Overall Rate of Morbidity | Determine the morbidity of intestinal or multivisceral transplantation for participants with unresectable at 90 days by monitoring severe adverse events as classified according to Clavien-Dindo grade and comprehensive complication index. | 90 days post operative | |
Secondary | Overall Rate of Morbidity | Determine the morbidity of intestinal or multivisceral transplantation for participants with unresectable at 12 months by monitoring severe adverse events as classified according to Clavien-Dindo grade and comprehensive complication index. | 12 months post operative | |
Secondary | Overall Rate of Mortality | Determine cancer-related and transplant-related mortality after intestinal or multivisceral transplantation in participants with unresectable PMP. | 12 months post operative |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04024917 -
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
|
N/A | |
Completed |
NCT02374411 -
Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients
|
N/A | |
Recruiting |
NCT02073500 -
Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies
|
||
Active, not recruiting |
NCT01427101 -
Results of CRS and Debulking in PMP Patients
|
N/A | |
Active, not recruiting |
NCT04982146 -
Intratumoral Bromelain + Acetylcysteine in Relapsed and Unresectable Pseudomyxoma Peritonei
|
Phase 1 | |
Completed |
NCT04088786 -
Phase I Trial HIPEC With Nal-irinotecan
|
Phase 1 | |
Active, not recruiting |
NCT02834169 -
French National Registry of Rare Peritoneal Surface Malignancies
|
N/A | |
Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A | |
Completed |
NCT02040142 -
Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C
|
Phase 2 | |
Withdrawn |
NCT04125225 -
What Are the Experiences of Patients With Pseudomyxoma Peritonei?
|
||
Not yet recruiting |
NCT03976973 -
BromAc for Recurrent Peritoneal Mucinous Tumour or Pseudomyxoma Peritonei
|
Phase 2 | |
Recruiting |
NCT01617382 -
Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed
|
||
Completed |
NCT01652794 -
Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer
|
Phase 1 | |
Completed |
NCT01126346 -
Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
|
N/A | |
Completed |
NCT05513183 -
Severe Neutropenia After HIPEC Using Mitomycin-C
|
||
Active, not recruiting |
NCT02834013 -
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
|
Phase 2 | |
Recruiting |
NCT03210298 -
International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)
|
||
Active, not recruiting |
NCT02387203 -
Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin
|
Phase 2 | |
Terminated |
NCT04665921 -
A Study of SGN-STNV in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05321329 -
Adjuvant CAPECITABINE in High Risk PSEUDOMYXOMA PERITONEI Patients
|
Phase 2 |